Valganciclovir
Administration
- Type: Antiviral
- Dosage Forms:
- Routes of Administration: Oral
- Common Trade Names:
Adult Dosing
- CMV infection: 900 mg PO BID
- CMV prophylaxis: 900 mg PO daily
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| CMV retinitis | 900mg PO q12hrs x 14 days then 900mg PO q24hrs x 7 days | Severe vision threatening with intraocular implant |
| CMV retinitis | 900mg PO q12hrs x 21 days then 900mg PO q24hrs x 7 days | Peripheral lesions |
Pediatric Dosing
- Neonatal CMV infection: 17 mg/kg PO daily BID x 12 weeks, then 17 mg/kg daily until 1 year of age
Indications by Disease
Special Populations
- Pregnancy Rating: Category C, fetal risk cannot be ruled out
- Lactation risk: infant risk cannot be ruled out
- Renal dosing
- CrCl 40-59 mL/min: 450 mg BID
- CrCl 25-39 mL/min: 450 mg once daily
- CrCl 10-24 mL/min: 450 mg every 2 days
- CrCl < 10 mL/min or on HD: not recommended
- Hepatic dosing:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Anemia/aplastic anemia, leukopenia, thrombocytopenia, pancytopenia
Common
- Nausea/vomiting, diarrhea
- Graft rejection
- Headache
- URI
- UTI
- Fever
- Tremor
Pharmacology
- Half-life: 4-10h
- Metabolism: Hepatic
- Excretion: Renal
Mechanism of Action
- Inhibits viral DNA synthesis